CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.

Autor:	Karam, Aya, Mjaess, Georges, Martinez Chanza, Nieves, Aoun, Fouad, Bou Kheir, George, Younes, Hadi, Kazzi, Hanane, Albisinni, Simone, Roumeguère, Thierry
Předmět:	GASTROINTESTINAL tumors treatment TREATMENT of lung tumors TUMOR treatment PROSTATE tumors treatment ONLINE information services EPITHELIAL cell tumors MESOTHELIOMA OVARIAN tumors CELLULAR therapy SYSTEMATIC reviews SMALL cell carcinoma CELL receptors CENTRAL nervous system tumors TREATMENT effectiveness CANCER patients DESCRIPTIVE statistics T cells MEDLINE IMMUNOTHERAPY SARCOMA EVALUATION
Zdroj:	Cancer Investigation; Nov2022, Vol. 40 Issue 10, p923-937, 15p
Abstrakt:	This systematic review aims to assess all the prospective studies published to date on the efficacy of CAR-T cell therapy in solid tumors. Databases searched were PubMed and Google Scholar from inception through May 1st 2021. Search query was (Chimeric antigen receptor) or (CAR-T) or (T-CAR). Twenty-nine prospective studies (265 patients) were included. Most published clinical trials are phase I. Clinical benefit was 100% in epithelial ovarian cancer, 70–82% in gastrointestinal tumors, 79% in mesothelioma, 63% in small-cell lung cancer, 24–67% in sarcoma, 50–62% in prostate cancer, and 45–50% in central nervous system tumors. No serious CAR-T cell specific serious toxicities were noted. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.